Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder that affects the blood vessels. A person with HHT may have blood vessels that have not developed properly and may have no ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

A multicenter research effort yielded findings that may allow for more effective and personalized treatment of an underrecognized but serious blood disorder.Extended follow-up of individuals with ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.

Area of focus: translational research in vascular biology, including studies on endothelial cells, platelets and other blood cells. When a patient presented with challenging nosebleeds and severe ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons. HHT’s hallmark symptom is chronic nosebleeds, which often ...

WATERTOWN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of ...

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for HHT ...

A phase 2 clinical trial has demonstrated that pomalidomide, used to treat bone marrow cancer, is safe and effective for managing hereditary hemorrhagic telangiectasia, a rare genetic bleeding ...

DURHAM, N.C., Aug. 16, 2022 /PRNewswire/ -- Bio Products Laboratory USA (BPL), a leading manufacturer of plasma-derived protein therapies, today presented initial data from the Hereditary Factor X ...